iBASIS Integrates Cutting Edge Multi-Protocol Signaling Firewall of Security Expert jtendo for Global Cloud-Based Network Protection
19.9.2022 08:00:00 EEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the integration of the cutting-edge multi-protocol signaling firewall of telecom security expert jtendo to its Managed Cloud-Based Security Portfolio, iBASIS Security iQ360.
The increase in the number of network protocols (also covering 5G), technologies, and roaming traffic creates a greater complexity requiring advanced features for testing and cross-protocol correlation to monitor, analyze, detect, and prevent security breaches. The strategic partnership combines jtendo security audit experience, deep technical knowledge of telco protocols, and cross-protocol correlation expertise with iBASIS’ unique international and managed cloud-based skills, with dedicated security centers in Americas, Europe, and Asia.
"The growing threat trend around today’s telecom networks drives the need for innovative security management solutions that can adapt quickly to new threats," says Guillaume Klein, iBASIS Vice President, Product Management. "We are thrilled to collaborate with jtendo to achieve effective threat management and be able to leverage their unique auditing and multiprotocol expertise to raise the level of protection even further."
"We are very proud to partner with one of the largest international signaling, voice, and data networks and complement iBASIS’ 360-degree intelligence-based solution," adds Piotr Szymański, jtendo CEO. "Mobile operators are increasingly searching for threat management that continuously adapts to their ever-changing network landscape, offering a flexible managed solution hosted on the IPX network is an effective way to secure their signaling network as an ongoing process. We are always there to support our customers in keeping their network safe in all areas."
The iBASIS Security iQ360 platform provides MNOs with a high level of process automation to assess vulnerability and address security risks with advanced auditing. The solution relies on in-depth visibility, monitoring, and attack detection complemented with automatic rule updates against continuously evolving threats.
iBASIS and jtendo will be part of WAS#16, September 19-22, in Cape Town and will jointly present real-world security cases at Stand# L10.
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 800+ LTE destinations.
iBASIS optimizes global connectivity, quality and security, so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, IoT and cloud communications to be first in their respective markets. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
ABOUT JTENDO
jtendo is the expert in telecom security, providing high-quality solutions and services to mobile network operators in more than 30 countries. jtendo secures networks against SS7, Diameter, and GTP vulnerabilities through a security suite headed by its proprietary SigWall (jtendo Signaling Firewall) solution.
With 90,000 TPS per single site in the largest SigWall installation, more than 1 million total TPS across all platforms and more than 100 million subscribers served by its platforms, jtendo is one of the world's most sought-after telecom and security specialists.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005001/en/
Contact information
Media Relations
Melissa Coffman
26FIVE Tech Lab
+1 202 251 1793
iBASIS@26FIVE.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
